Peer-reviewed veterinary case report
Microalbuminuria not linked to kidney azotemia in dogs on cisplatin
By Autio, Karoliina et al.Ā·Published in Journal of veterinary internal medicineĀ·2007Ā·Department of Clinical Sciences, United StatesĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Microalbuminuria is not associated with cisplatin-induced azotemia in dogs.
- Species:
- dog
Plain-English summary
A group of 32 dogs with cancer received cisplatin chemotherapy, which can sometimes lead to kidney problems. After 1 to 5 treatments, about 31% of the dogs developed elevated kidney markers, known as azotemia. However, the presence of microalbuminuria (a marker of kidney damage) did not help predict which dogs would experience kidney issues after treatment. This means that testing for microalbuminuria isn't a reliable way to assess kidney damage in dogs receiving cisplatin.
People also search for: dog cancer treatment side effects Ā· cisplatin kidney damage in dogs Ā· microalbuminuria in dogs
Abstract
BACKGROUND: Cisplatin is an effective antineoplastic agent but its use is limited by renal toxicity. Microalbuminuria is a marker of renal damage and might be an indicator of cisplatin-induced azotemia. NULL HYPOTHESIS: Microalbuminuria is not associated with azotemia in dogs treated with cisplatin. ANIMALS: This study used 32 client-owned dogs. METHODS: This was a prospective observational study in which cancer-bearing dogs were treated with cisplatin chemotherapy. Cisplatin-induced azotemia was defined as an increase of serum creatinine concentration above the reference range. Serum creatinine concentration, other routine tests of renal function, and microalbuminuria were measured after each cisplatin treatment. Variables potentially associated with azotemia were compared by use of Fisher's exact test and Wilcoxon's rank-sum test. RESULTS: Cisplatin-induced azotemia occurred in 10 (31%) dogs after 1-5 treatments. At each of the first 3 treatments, the proportions of dogs with microalbuminuria were similar between dogs with and without azotemia. CONCLUSIONS AND CLINICAL IMPORTANCE: Microalbuminuria measured after each treatment was not associated with azotemia through the first 3 treatments. Testing for microalbuminuria as a marker for cisplatin-induced renal damage is insensitive and not recommended.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18196726/